Status:
COMPLETED
Activation of the Endocannabinoid System and Cognition
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Post Traumatic Stress Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Recent data suggest that the cannabinoid-system is involved in stress regulation and posttraumatic stress disorder (PTSD). Low endocannabinoid signaling has been found in PTSD patients and might even ...
Detailed Description
Recent data suggest that the cannabinoid-system is involved in stress regulation and posttraumatic stress disorder (PTSD). Low endocannabinoid signaling has been found in PTSD patients and might even ...
Eligibility Criteria
Inclusion
- PTSD criteria fullfilled (patients only)
Exclusion
- All cases of physical illnesses and intake of medication (except oral contraceptives) (healthy controls only) will be excluded.
- Pregnant and lactating individuals will also be excluded. Participants with a positive urinary cannabinoid test (Cannabis 20 Pipettier-Drogenschnelltest (Urin), Diagnostik Nord GmbH) will also be excluded.
- psychiatric disorder according to DSM-5 (healthy controls only)
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2024
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT05226351
Start Date
March 1 2022
End Date
August 15 2024
Last Update
March 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätsmedizin Berlin
Berlin, Germany, 12203
2
Charite University
Berlin, Germany